Y Combinator is a startup accelerator that invests in a large number of startups twice a year. It created a new model for funding startups. Twice a year, the company invests a small amount of money ($150k) in a large number of startups. The startup accelerator works intensively with the companies for three months, to get them into the best possible shape and refine their pitch to investors. Each cycle culminates in Demo Day when the startups present their companies to a carefully selected, invite-only audience.

Y Combinator

FundersClub focuses on Seed and early stage investments. Investments include Coinbase, Instacart, Flexport, Le Tote, Teespring, Memebox, GitLab. FundersClub is the world's first online venture capital platform. Backed by Y Combinator, First Round Capital, Spark Capital, Intel Capital, Draper, Andreessen Horowitz, Felicis Ventures, and more; FundersClub Inc. was founded in 2012 and is based in the United States.

FundersClub

Fifty Years is a venture capital firm that backs founders using technology to solve the world's biggest problems.  Entrepreneur-run and based in San Francisco, Fifty Years invests in companies that inspire. Specifically, they fund companies that, if successful, will be both massively profitable and make a serious dent in achieving one or more of the Sustainable Development Goals.

Fifty Years

Pioneer Fund is a fund of 420+ Y Combinator alumni, investing in the top Y Combinator startups.

Pioneer Fund

Reinforced Ventures is focused on helping founders with both capital and expertise at seed or pre-seed stages leveraging our network of over 1,600 engineers, entrepreneurs, and scientists.

Reinforced Ventures

Backing engineers building awe, wonder, speed.

FAST — by GETTYLAB

NFX operates as a pre-seed & seed stage investor that is transforming how true innovators are funded for entrepreneurs. They believe that creating something of true significance starts with seeing things others do not. As Founders, they reinvented industries with this mindset. As investors, their approach is no different. They do this by asking ourselves one question - ideally, how should the startup experience work for Founders, both NFX and the whole ecosystem. NFX lens is always through the eyes of the Founder. The firm approach is to first build an early-stage experience for all Founders that is powered by more software. Second, to bring the founders they back exponential yet little-known techniques for network effects and growth. Third, to make visible the typically seen methods of technology's most impactful companies. Having built 10 companies with more than $10 billion in exits across multiple industries and geographies, they're entrepreneurs first because they're entrepreneurs first. And they are determined to guard the backs of the next generation of fearless founders.

North South Ventures is a cross-border venture capital fund that invests in early stage med companies. We are co-located in academic med superclusters (Stanford/UCSF and University of Toronto).  As a team, we have invested in over 350 medical portfolio companies and 40+ FDA approvals in the biotech, med device, and digital health/AI spaces with $4B+ in cumulative funding and three multi billion dollar IPOs since 2012.

North South Ventures

Boom Capital is a pre-seed fund for deeply technical, under-networked founders trying to build their companies. It was incorporated in 2017 and is based in San Francisco, California.

Boom Capital Ventures

Two Bear Capital invests in early-stage companies with disruptive innovations at the intersections of biotech, bioinformatics, machine learning / AI, and cybersecurity that deliver dramatically better solutions to the most critical problems affecting human health, security and wellness.

Two Bear Capital

Rolling Bay Ventures is a venture capital investing in seed, early and mid-stage and expansion companies.

Rolling Bay Ventures

BoxOne Ventures is a privately held investment firm that focuses on early-stage companies across all markets: biotech, fintech, agtech, healthcare, data, engineering, and AI/ML. We strive to balance the best elements of patient angel capital with the value-add often found at venture funds. You will often find us as the first cheque into a company. We invest our own capital and bring our experience as operators that have scaled many startups from founding to exit. We like partnering in the earliest days and continuing to support entrepreneurs with capital, expertise, and our network across their entire journey while making sure to never get in their way.

BoxOne Ventures

YC Continuity is an investment fund dedicated to supporting founders as they scale their companies.

Y Combinator Continuity Fund

WRF Capital supports groundbreaking research and early-stage companies that focus on life sciences and enabling technologies. WRF Capital is composed of the Washington Research Foundation and WRF Capital. It is a venture investment arm of the Washington Research Foundation. It works with entrepreneurs, research institutions, other investors, and industry partners to transform great ideas into successful Washington-based businesses. It was founded in 1981 and is based in Seattle, Washington.

WRF Capital

Talus Bio

Talus Bio is a drug discovery biotech startup working on drug development for gene regulators. The company integrates functional proteomics, automated biology, and machine learning to target challenging cancer transcription factors. The MARMOT (Multiplexed Assays for the Rational Modulation Of Transcription Factors) platform, developed by the company, leverages AI, advanced proteomics, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics in a groundbreaking manner.

Talus Biosciences develops novel therapeutics, focusing on previously undruggable transcription factors—proteins that regulate all genes in a person's genetic material by attaching to DNA and activating or deactivating the switches that determine gene activity.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Talus Bio tacks on $11M to target hard-to-reach transcription factors

Talus Biosciences develops novel therapeutics, focusing on previously undruggable transcription factors—proteins that regulate all genes in a person's genetic material by attaching to DNA and activating or deactivating the switches that determine gene activity.The company leverages its proprietary drug discovery platform, Multiplexed Assays for Rational Modulation of Transcription Factors (MARMOT), which combines AI, synthetic chemistry, automated biology, advanced proteomics, synthetic chemistry, and computational methods to accelerate the discovery and development of novel drugs.Talus Bio’s initial focus lies in oncology and the issues related to transcription factors of cancer. It also intends to explore other disease areas, including inflammatory, fibrotic, neurological, and cardiometabolic disorders. As of September 2023, the company’s pipeline consisted of four programs, including its TBXT program for chordoma (a spinal cord cancer resistant to chemotherapy), which specifically targets the transcription factor, TBXT, to kill cancer cells.Funding and financials<a href="https://sp-edge.com/updates/21166">In August 2023 </a>, Talus Bio secured USD 2.3 million in non-dilutive grant funding from the Andy Hill Cancer Research Endowment (CARE) Fund and an additional USD 2 million small business innovation research (SBIR) grant from the National Institutes of Health. The funds were used to speed up the development of novel transcription factor inhibitors for two pediatric cancers and accelerate the development of transcription factor drugs.

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response. 

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

<div>
 
 The AI drug discovery startup based in Seattle, Talus Biosciences, raised USD 11.2 million in a seed+ funding round. The round was led by Two Bear Capital, with other participants that included WRF Capital, NFX, and YC Continuity Fund.
 Talus Bio aims to use this funding to advance its therapeutic programs. These programs include targeting Brachyury-driven cancers and a transcription factor implicated in prostate cancer which is currently undruggable. Additionally, the funding will also help speed up the expansion of the company's unique MARMOT platform.
 
</div>

Talus Bio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless